UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2008

 

OR

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

FOR THE TRANSITION PERIOD FROM           TO

 

COMMISSION FILE NUMBER:  001-15405

 

AGILENT TECHNOLOGIES, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 

DELAWARE

 

77-0518772

(STATE OR OTHER JURISDICTION OF

 

(IRS EMPLOYER

INCORPORATION OR ORGANIZATION)

 

IDENTIFICATION NO.)

 

 

 

5301 STEVENS CREEK BLVD.,

 

 

SANTA CLARA, CALIFORNIA

 

95051

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(ZIP CODE)

 

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (408) 553-7777

 

 

(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)

 

INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS.  YES  x   NO  o

 

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS A LARGE ACCELERATED FILER, AN ACCELERATED FILER, A NON-ACCELERATED FILER, OR A SMALLER REPORTING COMPANY. SEE DEFINITIONS OF “LARGE ACCELERATED FILER,” “ACCELERATED FILER,” AND “SMALLER REPORTING COMPANY” IN RULE 12b-2 OF THE EXCHANGE ACT.

 

Large accelerated filer  x

Accelerated filer  o

Non-accelerated filer  o

Smaller Reporting Company o

 

 

(do not check if a
smaller reporting company)

 

 

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS A SHELL COMPANY (AS DEFINED IN RULE 12b-2 OF THE EXCHANGE ACT).  YES  o   NO  x

 

INDICATE THE NUMBER OF SHARES OUTSTANDING OF EACH OF THE ISSUER’S CLASSES OF COMMON STOCK, AS OF THE LATEST PRACTICABLE DATE.

 

CLASS

 

OUTSTANDING APRIL 30, 2008

COMMON STOCK, $0.01 PAR VALUE

 

360,108,255 SHARES

 

 



 

AGILENT TECHNOLOGIES, INC.

TABLE OF CONTENTS

 

 

 

Page
Number

Part I.

Financial Information

 

3

 

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

3

 

 

Condensed Consolidated Statement of Operations

3

 

 

Condensed Consolidated Balance Sheet

4

 

 

Condensed Consolidated Statement of Cash Flows

5

 

 

Notes to Condensed Consolidated Financial Statements

6

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

28

 

Item 4.

Controls and Procedures

28

Part II.

Other Information

 

28

 

Item 1.

Legal Proceedings

28

 

Item 1A.

Risk Factors

29

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

37

 

Item 4.

Submission of Matters to a Vote of Security Holders

37

 

Item 6.

Exhibits

38

Signature

 

 

39

Exhibit Index

 

 

40

 

2



 

PART I — FINANCIAL INFORMATION

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

AGILENT TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in millions, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended
April 30,

 

Six Months Ended
April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

Net revenue:

 

 

 

 

 

 

 

 

 

Products

 

$

1,214

 

$

1,095

 

$

2,375

 

$

2,160

 

Services and other

 

242

 

225

 

474

 

440

 

Total net revenue

 

1,456

 

1,320

 

2,849

 

2,600

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Cost of products

 

512

 

461

 

1,013

 

924

 

Cost of services and other

 

137

 

129

 

273

 

255

 

Total costs

 

649

 

590

 

1,286

 

1,179

 

Research and development

 

183

 

173

 

364

 

341

 

Selling, general and administrative

 

433

 

426

 

874

 

854

 

Total costs and expenses

 

1,265

 

1,189

 

2,524

 

2,374

 

Income from operations

 

191

 

131

 

325

 

226

 

Interest income

 

27

 

44

 

66

 

94

 

Interest expense

 

(29

)

(22

)

(59

)

(45

)

Other income (expense), net

 

7

 

3

 

11

 

4

 

Income before taxes

 

196

 

156

 

343

 

279

 

Provision for income taxes

 

23

 

33

 

50

 

6

 

Net income

 

$

173

 

$

123

 

$

293

 

$

273

 

 

 

 

 

 

 

 

 

 

 

Net income per share – basic:

 

$

0.48

 

$

0.31

 

$

0.80

 

$

0.67

 

Net income per share – diluted:

 

$

0.47

 

$

0.30

 

$

0.78

 

$

0.66

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing net income per share:

 

 

 

 

 

 

 

 

 

Basic

 

363

 

402

 

367

 

405

 

Diluted

 

370

 

413

 

376

 

416

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3



 

AGILENT TECHNOLOGIES, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEET

(in millions, except par value and share amounts)

(Unaudited)

 

 

 

April 30,
2008

 

October 31,
2007

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

1,710

 

$

1,826

 

Short-term investments

 

30

 

 

Accounts receivable, net

 

791

 

735

 

Inventory

 

674

 

643

 

Restricted cash and cash equivalents

 

1,572

 

 

Other current assets

 

408

 

467

 

Total current assets

 

5,185

 

3,671

 

Property, plant and equipment, net

 

809

 

801

 

Goodwill

 

630

 

558

 

Other intangible assets, net

 

237

 

178

 

Restricted cash and cash equivalents

 

12

 

1,615

 

Long-term investments

 

274

 

194

 

Other assets

 

527

 

537

 

Total assets

 

$

7,674

 

$

7,554

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

312

 

$

323

 

Employee compensation and benefits

 

433

 

432

 

Deferred revenue

 

321

 

249

 

Income and other taxes payable

 

106

 

522

 

Short-term debt

 

1,752

 

 

Other accrued liabilities

 

120

 

137

 

Total current liabilities

 

3,044

 

1,663

 

Long-term debt

 

 

1,500

 

Senior notes

 

622

 

587

 

Retirement and post-retirement benefits

 

121

 

141

 

Other long-term liabilities

 

731

 

429

 

Total liabilities

 

4,518

 

4,320

 

Stockholders’ equity:

 

 

 

 

 

Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding

 

 

 

Common stock; $0.01 par value; 2 billion shares authorized; 556 million shares at April 30, 2008 and 551 million shares at October 31, 2007 issued

 

6

 

6

 

Treasury stock at cost; 196 million shares at April 30, 2008 and 181 million shares at October 31, 2007

 

(6,969

)

(6,469

)

Additional paid-in-capital

 

7,251

 

7,117

 

Retained earnings

 

2,391

 

2,172

 

Accumulated other comprehensive income

 

477

 

408

 

Total stockholders’ equity

 

3,156

 

3,234

 

Total liabilities and stockholders’ equity

 

$

7,674

 

$

7,554

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4



 

AGILENT TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in millions)

(Unaudited)

 

 

 

Six Months Ended
April 30,

 

 

 

2008

 

2007

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

293

 

$

273

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

100

 

93

 

Share-based compensation

 

49

 

76

 

Deferred taxes

 

58

 

(8

)

Excess and obsolete inventory-related charges

 

8

 

8

 

Translation gain from liquidation of a subsidiary

 

(25

)

 

Asset impairment charges

 

3

 

4

 

Net loss (gain) on sale of investments

 

4

 

(2

)

Net loss (gain) on sale of assets

 

1

 

(6

)

Other

 

2

 

1

 

Changes in assets and liabilities:

 

 

 

 

 

Accounts receivable

 

(25

)

(4

)

Inventory

 

(36

)

(30

)

Accounts payable

 

19

 

(31

)

Employee compensation and benefits

 

 

10

 

Income taxes and other taxes payable

 

(99

)

15

 

Other current assets and liabilities

 

67

 

55

 

Other long-term assets and liabilities

 

(90

)

(59

)

Net cash provided by operating activities

 

329

 

395

 

Cash flows from investing activities:

 

 

 

 

 

Investments in property, plant and equipment

 

(71

)

(79

)

Proceeds from sale of property, plant and equipment

 

14

 

8

 

Purchase of investments

 

(255

)

 

Proceeds from sale of investments

 

114

 

12

 

Change in restricted cash and cash equivalents, net

 

31

 

2

 

Purchase of minority interest

 

(14

)

 

Acquisitions of businesses and intangible assets, net of cash acquired

 

(130

)

(72

)

Net cash used in investing activities

 

(311

)

(129

)

Cash flows from financing activities:

 

 

 

 

 

Issuance of common stock under employee stock plans

 

84

 

147

 

Proceeds from revolving credit facility

 

250

 

 

Treasury stock repurchases

 

(500

)

(636

)

Net cash used in financing activities

 

(166

)

(489

)

 

 

 

 

 

 

Effect of exchange rate movements

 

32

 

11

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

(116

)

(212

)

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

1,826

 

2,262

 

Cash and cash equivalents at end of period

 

$

1,710

 

$

2,050

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5



 

AGILENT TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. OVERVIEW

 

Agilent Technologies, Inc. (“we”, “Agilent” or the “company”), incorporated in Delaware in May 1999, is a measurement company, providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries.

 

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, all dates refer to our fiscal year and fiscal quarters.

 

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Reclassifications. Long-term investments as of October 31, 2007 have been reclassified from other assets to conform to the more detailed presentation used in 2008.

 

Basis of Presentation. We have prepared the accompanying financial data for the three and six months ended April 30, 2008 and 2007 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The following discussion should be read in conjunction with our 2007 Annual Report on Form 10-K.

 

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary to present fairly our condensed consolidated balance sheet as of April 30, 2008 and October 31, 2007, condensed consolidated statement of operations for the three and six months ended April 30, 2008 and 2007, and condensed consolidated statement of cash flows for the six months ended April 30, 2008 and 2007.

 

The preparation of condensed consolidated financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, investment impairments, share-based compensation, retirement and post-retirement plan assumptions, valuation of long-lived assets and accounting for income taxes.

 

3. NEW ACCOUNTING PRONOUNCEMENTS

 

In June 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109” (“FIN No. 48”). FIN No. 48 defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authority and provides guidance on the derecognition, measurement and classification of income tax uncertainties, along with any related interest and penalties. FIN No. 48 is effective for fiscal years beginning after December 15, 2006, and was effective for Agilent on November 1, 2007.  See Note 5, “Provision for Taxes”, for additional information, including the effects of adoption on our consolidated financial statements.

 

Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“SFAS No. 157”) is effective for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position (“FSP”) No. 157-1, “Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13” (“FSP No. 157-1”) and FASB Staff Position No. 157-2, “Effective Date of FASB Statement No. 157” (“FSP No. 157-2”). FSP No. 157-1 amends SFAS No. 157 to remove certain leasing transactions from its scope. FSP No. 157-2 delays the effective date of SFAS No. 157 for nonfinancial assets and nonfinancial liabilities, except for certain items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). We are currently evaluating the impact of SFAS No. 157 on our consolidated financial statements for items within the scope of FSP No. 157-2 which will become effective for fiscal years beginning after November 15, 2008 and interim periods within those fiscal years.

 

6



 

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities - an amendment of FASB Statement No. 133”, (“SFAS No. 161”), which requires additional disclosures about objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for under SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities”, and related interpretations, and how the derivative instruments and related hedged items affect our financial statements. SFAS No. 161 also requires disclosures about credit risk-related contingent features in derivative agreements.  SFAS No. 161 is effective for fiscal years and interim periods beginning after November 15, 2008 and will be applied prospectively. We are currently evaluating the impact of SFAS No. 161 on our consolidated financial statements.

 

In April 2008, the FASB issued FASB Staff Position No. 142-3, “Determination of the Useful Life of Intangible Assets” (“FSP No. 142-3”). FSP No. 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement No. 142, “Goodwill and Other Intangible Assets” (“SFAS No. 142”).  FSP No. 142-3 is effective for financial statements issued for fiscal years beginning after December 15, 2008 and will be applied prospectively. We are currently evaluating the impact of adopting FSP No. 142-3 on our consolidated financial statements.

 

4. SHARE-BASED COMPENSATION

 

We follow the accounting provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payment” (“SFAS No. 123 (R)”), for share-based awards granted to employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan (“ESPP”) and performance share awards under our Long-Term Performance Program (“LTPP”) using the estimated grant date fair value method of accounting in accordance with SFAS No. 123 (R).

 

The impact on our results for share-based compensation was as follows:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions, except

 

(in millions, except

 

 

 

per share data)

 

per share data)

 

Cost of products

 

$

4

 

$

11

 

$

11

 

$

21

 

Research and development

 

3

 

8

 

8

 

14

 

Selling, general and administrative

 

12

 

21

 

30

 

41

 

Total share-based compensation expense

 

$

19

 

$

40

 

$

49

 

$

76

 

 

 

 

 

 

 

 

 

 

 

Impact on net income per share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.05

 

$

0.10

 

$

0.13

 

$

0.19

 

Diluted

 

$

0.05

 

$

0.10

 

$

0.13

 

$

0.18

 

 

Share-based compensation capitalized within inventory at April 30, 2008 and 2007 was zero and $1 million, respectively. The windfall tax benefit realized from exercised stock options and similar awards was immaterial for the three and six months ended April 30, 2008 and 2007.

 

7



 

The following assumptions were used during the three and six months ended April 30, 2008 and 2007 to estimate the fair value of the options granted, ESPP purchases and a LTPP grant. During the three months ended April 30, 2008, no grants were made under any of our share-based payment award plans as reflected in the assumption table below:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

 

 

 

 

 

 

 

 

Stock Option Plans:

 

 

 

 

 

 

 

 

 

Weighted average risk-free interest rate

 

 

4.4

%

3.2

%

4.6

%

Dividend yield

 

 

0

%

0

%

0

%

Weighted average volatility

 

 

26

%

33

%

30

%

Expected life

 

 

4.6 yrs

 

4.6 yrs

 

4.6 yrs

 

 

 

 

 

 

 

 

 

 

 

ESPP:

 

 

 

 

 

 

 

 

 

Weighted average risk-free interest rate

 

 

 

3.8

%

4.8

%

Dividend yield

 

 

 

0

%

0

%

Weighted average volatility

 

 

 

32

%

32

%

Expected life

 

 

 

0.5-1 yr

 

0.5-2 yrs

 

 

 

 

 

 

 

 

 

 

 

LTPP:

 

 

 

 

 

 

 

 

 

Volatility of Agilent shares

 

 

30

%

27

%

31

%

Volatility of selected peer-company shares

 

 

15%-57

%

17%-52

%

15%-57

%

Price-wise correlation with selected peers

 

 

29

%

24

%

29

%

 

The fair value of share-based awards for employee stock option awards and employee stock purchases made under our ESPP was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP were valued using a Monte Carlo simulation model. Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective and complex assumptions, including the option’s expected life and the price volatility of the underlying stock. The estimated fair value of restricted stock unit awards is determined based on the market price of Agilent’s common stock on the date of grant.

 

The expected stock price volatility assumption for employee stock option awards and our ESPP was determined using the implied volatility for the six months ended April 30, 2008 and 2007. We estimate the stock price volatility using the implied volatility of Agilent’s publicly traded, similarly priced, stock options. We have determined that implied volatility is more reflective of market conditions and a better indicator of expected volatility than using historical volatility or a combined method of determining volatility.

 

5. PROVISION FOR TAXES

 

We recorded $23 million and $50 million of income tax provision for the three and six months ended April 30, 2008. The tax provision for the three and six months ended April 30, 2008 both include a benefit of $12 million for effectively settled issues related to foreign audits. The tax provision for the three and six months ended April 30, 2008 include a benefit of $2 million and expense of $3 million, respectively, for interest and penalties. The income tax provision for the six months ended April 30, 2007 includes a benefit of $50 million related to the reversal of a tax reserve for potential non-U.S. exposures where the statute of limitations expired. The provision for taxes was recorded for income generated in jurisdictions other than the U.S., U.K. and the Netherlands in which we have valuation allowances. We intend to maintain partial or full valuation allowances in the U.S., U.K. and the Netherlands until sufficient positive evidence exists to support the reversal of the valuation allowances.

 

Effective at the beginning of the first quarter of 2008, we adopted FIN No. 48. FIN No. 48 contains a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with SFAS No. 109, “Accounting for Income Taxes.” The first step is to evaluate each uncertain tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon ultimate settlement.

 

As a result of the implementation of FIN No. 48, we increased the liability for net unrecognized tax benefits by $74 million, and accounted for the increase as a cumulative effect of a change in accounting principle that resulted in a decrease to retained earnings of $74 million. The total amount of gross unrecognized tax benefits as of the date of adoption was $909 million. We historically classified unrecognized tax benefits in current taxes payable, or as reductions to tax receivables or net deferred tax assets when appropriate. As a result of adopting FIN No. 48, approximately $355 million of unrecognized tax benefits and related interest and penalties were reclassified to long-term income taxes payable from current taxes payable. Most of these gross unrecognized tax benefits would affect the effective tax rate, if realized.

 

8



 

We continue to include interest and penalties related to unrecognized tax benefits within the provision for income taxes on the condensed consolidated statements of operations. As of the date of adoption of FIN No. 48, we had accrued $35 million for the payment of interest and penalties relating to unrecognized tax benefits.

 

In the U.S. and other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2000.  Although the timing and outcome of audit settlements is highly uncertain, we do not believe that the unrecognized tax benefits would materially change in the next 12 months.

 

Our U.S. federal income tax returns for 2000 through 2002 have been under audit by the Internal Revenue Service (“IRS”). In August 2007, we received a Revenue Agent’s Report (“RAR”). In the RAR, the IRS proposes to assess a net tax deficiency, after applying available net operating losses from the years under audit and undisputed tax credits, for those years of approximately $405 million, plus penalties of approximately $160 million and interest. If the IRS were to fully prevail, our net operating loss and tax credits generated in recent years would be utilized earlier than they otherwise would have been, and our annual effective tax rate will have increased as a result. The RAR addresses several issues. One issue, however, relating to the use of Agilent’s brand name by our foreign affiliates, accounts for a majority of the claimed tax deficiency. We believe that the claimed IRS adjustment for this issue in particular is inconsistent with applicable tax laws and that we have meritorious defenses to this claim. Therefore, we have not included any tax for this item in our tax provision for 2007 or for either of the first two quarters of 2008. We have filed a formal protest and expect to meet with the Appeals Office of the IRS. In the protest, we have vigorously opposed the claim associated with Agilent’s brand name, and most of the other claimed adjustments proposed in the RAR. In April of 2008, we received a rebuttal to our formal protest, and after reviewing the IRS’s arguments, our assessment of the risks remains the same. The final resolution of the proposed adjustments is uncertain and may take several years. Based on current information, it is our opinion that the ultimate disposition of these matters is unlikely to have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

We are subject to ongoing tax examinations of our tax returns by the Internal Revenue Service and other tax authorities in various jurisdictions. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. These assessments can require considerable judgments. If our estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the accrual of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary.

 

6. NET INCOME PER SHARE

 

The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions)

 

Numerator:

 

 

 

 

 

 

 

 

 

Net income

 

$

173

 

$

123

 

$

293

 

$

273

 

Denominators:

 

 

 

 

 

 

 

 

 

Basic weighted-average shares

 

363

 

402

 

367

 

405

 

Potentially dilutive common stock equivalents

 

7

 

11

 

9

 

11

 

Diluted weighted-average shares

 

370

 

413

 

376

 

416

 

 

The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense required by SFAS No. 123 (R).

 

The following table presents options to purchase shares of common stock, which were not included in the computations of diluted net income per share because they were anti-dilutive.

 

 

 

Three Months Ended
April  30,

 

Six Months Ended
April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

Options to purchase shares of common stock (in millions)

 

19

 

7

 

7

 

7

 

Weighted-average exercise price

 

$

36

 

$

44

 

$

45

 

$

44

 

Average common stock price

 

$

31

 

$

33

 

$

33

 

$

33

 

 

9



 

7. SHORT-TERM DEBT AND SHORT-TERM RESTRICTED CASH & CASH EQUIVALENTS

 

  The following table summarizes the company’s short-term debt as of April 30, 2008:

 

 

 

April 30,
2008

 

 

 

(in millions)

 

World Trade debt

 

$

1,500

 

Credit facility

 

250

 

Other

 

2

 

Total short-term debt

 

$

1,752

 

 

Short-Term Debt

 

In January 2006, Agilent Technologies World Trade, Inc., a consolidated wholly owned subsidiary of Agilent (“World Trade”), entered into a Master Repurchase Agreement and related Confirmation (together, the “Repurchase Agreement”) with a counterparty pursuant to which World Trade sold 15,000 Class A preferred shares of one of its wholly owned subsidiaries to the counterparty, having an aggregate liquidation preference of $1.5 billion (the “Purchased Securities”).

 

On December 7, 2007, Agilent and World Trade entered into an amendment to the Repurchase Agreement among Agilent, Merrill Lynch Capital Corporation (“Merrill Lynch”) and World Trade (the “Related Agreement”). As provided in the Related Agreement, World Trade is obligated to make quarterly payments to the counterparty at a rate per annum equal to either (i) the cost of funds to the counterparty plus 20 basis points, or (ii) three-month London inter-bank offered rate (“LIBOR”) plus 52 basis points. Also, at any time after February 5, 2008, Merrill Lynch may require that World Trade accelerate the date of repurchase of all or any portion of the Purchased Securities to a date designated by Merrill Lynch that is no earlier than 120 days from the date that Merrill Lynch provides notice. Due to this amendment, in the first quarter of 2008, we reclassified the $1.5 billion debt owed by World Trade from long-term to short-term debt in our condensed consolidated balance sheet. On March 18, 2008, World Trade received a notice from Merrill Lynch that it had accelerated the obligation to repurchase the Purchased Securities to July 16, 2008 at a repurchase price of $1.5 billion.

 

Credit Facility

 

On May 11, 2007, we entered into a five-year credit agreement, which provides for a $300 million unsecured credit facility that will expire on May 11, 2012. As of April 30, 2008, we had an outstanding balance of $250 million on the credit facility and it has been classified as short-term debt in our condensed consolidated balance sheet. On May 20, 2008 we paid the outstanding balance in full. Should further borrowings be made under the facility and the World Trade repurchase obligation is not satisfied on or before June 16, 2008, an “event of default” will occur under the credit agreement.  If an event of default occurred, the lenders would have the option to make any outstanding borrowings under the credit facility immediately due and payable.

 

Short-Term Restricted Cash & Cash Equivalents

 

As of April 30, 2008, $1,572 million was reported as short-term restricted cash and cash equivalents on our condensed consolidated balance sheet. This amount consists of short-term restricted commercial paper maintained in connection with our obligations per the Repurchase Agreement mentioned above.

 

8. INVENTORY

 

 

 

April 30,
2008

 

October 31,
2007

 

 

 

(in millions)

 

Finished goods

 

$

328

 

$

313

 

Work in progress

 

50

 

44

 

Raw materials

 

296

 

286

 

Total inventory

 

$

674

 

$

643

 

 

10



 

9. GOODWILL AND OTHER INTANGIBLE ASSETS

 

The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2008:

 

 

 

Electronic
Measurement

 

Bio-analytical
Measurement

 

Total

 

 

 

(in millions)

 

Goodwill as of October 31, 2007

 

$

317

 

$

241

 

$

558

 

Foreign currency translation impact

 

22

 

 

22

 

Goodwill arising from acquisitions

 

6

 

44

 

50

 

Goodwill as of April 30, 2008

 

$

345

 

$

285

 

$

630

 

 

The components of other intangibles as of April 30, 2008 and October 31, 2007 are shown in the table below:

 

 

 

Purchased Other Intangible Assets

 

 

 

Gross
Carrying
Amount

 

Accumulated
Amortization

 

Net Book
Value

 

 

 

(in millions)

 

As of October 31, 2007:

 

 

 

 

 

 

 

Purchased technology

 

$

280

 

$

173

 

$

107

 

Trademark/tradename

 

31

 

1

 

30

 

Customer relationships

 

82

 

41

 

41

 

Total

 

$

393

 

$

215

 

$

178

 

As of April 30, 2008:

 

 

 

 

 

 

 

Purchased technology

 

$

349

 

$

190

 

$

159

 

Trademark/tradename

 

31

 

2

 

29

 

Customer relationships

 

98

 

49

 

49

 

Total

 

$

478

 

$

241

 

$

237

 

 

We recorded $50 million of goodwill and $85 million of other intangibles during the six months ended April 30, 2008, related primarily to three acquisitions and a purchase of the remaining unowned portion of a joint venture. The larger acquisition is described below.  Pro forma disclosures are not presented for these acquisitions, as they are not required.

 

On December 18, 2007, we completed the acquisition of  Velocity11, a designer, manufacturer, and marketer of robotic solutions. The aggregate purchase price was approximately $111 million in cash used to purchase 100 percent of Velocity11’s outstanding common shares and vested common stock options that Velocity11 employees held on the close date.

 

Amortization of intangible assets was $13 million and $26 million for the three and six months ended April 30, 2008 and $8 million and $16 million for the same periods in the prior year.  Future amortization expense related to existing purchased intangible assets is estimated to be $25 million for the remainder of 2008, $44 million for 2009, $39 million for 2010, $36 million for 2011, $29 million for 2012, $18 million for 2013 and $46 million thereafter.

 

10. INVESTMENTS

 

The following table summarizes the company’s investments as of April 30, 2008 and October 31, 2007:

 

 

 

April 30,
2008

 

October 31,
2007

 

 

 

(in millions)

 

Short-Term

 

 

 

 

 

Available-for-sale investments

 

$

30

 

$

 

Total

 

$

30

 

$

 

Long-Term

 

 

 

 

 

Cost method investments

 

$

22

 

$

24

 

Trading securities

 

63

 

72

 

Available-for-sale investments

 

189

 

98

 

Total

 

$

274

 

$

194

 

 

11



 

Cost method investments consist of non-marketable equity securities and are accounted for at historical cost. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings. Investments designated as available-for-sale are reported at fair value, with unrealized gains and losses, net of tax, included in stockholders’ equity.

 

Available-for-sale investments at estimated fair value were as follows as of April 30, 2008 and October 31, 2007:

 

 

 

April 30, 2008

 

October 31, 2007

 

 

 

Cost

 

Gross
Unrealized
Gains

 

Gross
Unrealized
Losses

 

Estimated
Fair
Value

 

Cost

 

Gross
Unrealized
Gains

 

Gross
Unrealized
Losses

 

Estimated
Fair
Value

 

 

 

(in millions)

 

Debt securities

 

$

136

 

$

 

$

(4

)

$

132

 

$

 

$

 

$

 

$

 

Equity securities

 

4

 

11

 

 

15

 

4

 

22

 

 

26

 

Other

 

61

 

11

 

 

 

72

 

55

 

17

 

 

 

72

 

 

 

$

201

 

$

22

 

$

(4

)

$

219

 

$

59

 

$

39

 

$

 

$

98

 

 

Other represents shares we own in two special funds that target underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities.  These funds are held for employee benefits in Germany.

 

In February 2008, Agilent traded an externally managed short-term investment for the underlying securities of the investment and now manages those investments internally. The securities received were fixed income debt securities and are held as available-for-sale.  Agilent estimated the fair values based on quoted market prices or pricing models using current market rates. These estimated fair values may not be representative of actual values that could have been realized as of April 30, 2008 or that will be realized in the future.

 

Contractual maturities of available-for-sale debt securities were as follows at April 30, 2008:

 

 

 

Cost

 

Estimated Fair
Value

 

 

 

(in millions)

 

 

 

 

 

 

 

Due in less than 1 year

 

$

32

 

$

30

 

Due in 1-5 years

 

63

 

61

 

Due after 5 years

 

41

 

41

 

 

 

$

136

 

$

132

 

 

All of our investments, excluding trading securities, are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment.

 

Charges related to other than temporary impairments were $2 million and zero for the three months ended April 30, 2008 and 2007, respectively. For the six months ended April 30, 2008 and 2007, charges related to other than temporary impairments were $2 million for both periods. These impairment charges were recorded in other income (expense), net in the condensed consolidated statement of operations.

 

Unrealized losses on our trading securities portfolio were $6 million and zero for the three months ended April 30, 2008 and 2007, respectively. For the six months ended April 30, 2008 and 2007, unrealized gains and losses on our trading securities were

 

12



 

unrealized losses of $8 million and unrealized gains of $4 million, respectively. These amounts have been included in other income (expense), net in the condensed consolidated statement of operations.

 

Realized losses from the sale of available-for-sale securities were $3 million and zero for the three months ended April 30, 2008 and 2007, respectively. Realized gains and losses from the sale of available-for-sale securities were $4 million and $2 million for the six months ended April 30, 2008 and 2007, respectively. Realized gains and losses from the sale of cost method securities were immaterial for the three and six months ended April 30, 2008 and 2007, respectively. These amounts have been included in other income (expense), net in the condensed consolidated statement of operations.

 

11. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

 

Components of net periodic costs. For the three and six months ended April 30, 2008 and 2007, our net pension and post retirement benefit costs were comprised of the following:

 

 

 

Pensions

 

 

 

 

 

 

 

U.S. Plans

 

Non-U.S.
Plans

 

U.S. Post Retirement
Benefit Plans

 

 

 

Three Months Ended April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions)

 

Service cost—benefits earned during the period

 

$

9

 

$

10

 

$

10

 

$

9

 

$

1

 

$

1

 

Interest cost on benefit obligation

 

9

 

10

 

19

 

16

 

7

 

7

 

Expected return on plan assets

 

(14

)

(14

)

(28

)

(23

)

(8

)

(7

)

Amortization and deferrals:

 

 

 

 

 

 

 

 

 

 

 

 

 

Actuarial (gain) loss

 

(3

)

(1

)

5

 

8

 

 

 

Prior service cost

 

 

 

 

 

(3

)

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total net plan (income) costs

 

$

1

 

$

5

 

$

6

 

$

10

 

$

(3

)

$

(1

)

 

 

 

Pensions

 

 

 

 

 

 

 

U.S. Plans

 

Non-U.S.
Plans

 

U.S. Post Retirement 
Benefit Plans

 

 

 

Six Months Ended April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions)

 

Service cost—benefits earned during the period

 

$

18

 

$

20

 

$

19

 

$

18

 

$

2

 

$

2

 

Interest cost on benefit obligation

 

19

 

20

 

38

 

32

 

14

 

14

 

Expected return on plan assets

 

(28

)

(28

)

(55

)

(46

)

(16

)

(14

)

Amortization and deferrals:

 

 

 

 

 

 

 

 

 

 

 

 

 

Actuarial (gain) loss

 

(6

)

(2

)

10

 

16

 

 

 

Prior service cost

 

 

 

 

 

(6

)

(4

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net plan costs (income)

 

3

 

10

 

12

 

20

 

(6

)

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Curtailments and settlements

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total net plan (income) costs

 

$

3

 

$

9

 

$

12

 

$

20

 

$

(6

)

$

(2

)

 

For the U.S. plans, because of lump sum payouts during the six  months ended April 30, 2007, we recorded a $1 million settlement gain in accordance with SFAS No. 88, “Employers’ Accounting for Settlements and Curtailments of Defined Benefit Pension Plans and for Termination Benefits.

 

We contributed approximately zero and $2 million to our U.S. defined benefit plans during the three and six months ended April 30, 2008 and zero and $8 million respectively, for the same periods in 2007. We contributed approximately $9 million and $19 million to our non-U.S. defined benefit plans during the three and six months ended April 30, 2008 and $7 million and $16 million, respectively, for the same periods in 2007. We expect to contribute approximately $21 million to our non-U.S. defined benefit plans during the remainder of fiscal 2008.

 

13



 

12. WARRANTIES

 

We accrue for warranty costs in accordance with Statement of Financial Accounting Standards No. 5, “Accounting for Contingencies”, based on historical trends in warranty charges as a percentage of gross product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. Our warranty terms typically extend for one year from the date of delivery.

 

 

 

FY 2008

 

FY 2007

 

 

 

(in millions)

 

Beginning balance as of November 1,

 

$

29

 

$

29

 

Accruals for warranties issued during the period

 

25

 

29

 

Changes in estimates

 

(1

)

(1

)

Settlements made during the period

 

(25

)

(28

)

Ending balance as of April 30,

 

$

28

 

$

29

 

 

13. RESTRUCTURING

 

Our FY2005 Plan, announced in the fourth quarter of 2005, is largely complete.  The remaining obligations under this and previous plans relate primarily to lease obligations that are expected to be satisfied over approximately the next four years.

 

A summary of restructuring activity for the six months ended April 30, 2008 is shown in the table below:

 

 

 

Workforce
Reduction

 

Consolidation
of Excess
Facilities

 

Total

 

 

 

(in millions)

 

Ending balance as of October 31, 2007

 

$

1

 

$

31

 

$

32

 

Income statement expense

 

 

(4

)

(4

)

Cash payments

 

(1

)

(7

)

(8

)

Ending balance as of April 30, 2008

 

$

 

$

20

 

$

20

 

 

The restructuring accrual for all plans, which totaled $20 million as of April 30, 2008 and $32 million as of October 31, 2007, is recorded in other accrued liabilities and other long-term liabilities on the condensed consolidated balance sheet and represents estimated future cash outlays.

 

In the first quarter of 2008 we reduced our estimated liability relating to the consolidation of excess facilities by $4 million due to changes in the underlying property markets.

 

A summary of the charges in the statement of operations resulting from all restructuring plans is shown below:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions)

 

(in millions)

 

Cost of products

 

$

 

$

3

 

$

 

$

6

 

Research and development

 

 

 

 

1

 

Selling, general and administrative

 

 

4

 

(4

)

9

 

Total restructuring and asset impairment charges

 

$

 

$

7

 

$

(4

)

$

16

 

 

14. SENIOR NOTES

 

In October 2007, the company issued an aggregate principal amount of $600 million in senior notes. The senior notes were issued at 99.60% of their principal amount. The notes will mature on November 1, 2017, bear interest at a fixed rate of 6.50% per annum, payable semi-annually on May 1 and November 1 of each year, commencing on May 1, 2008. The senior notes are unsecured and will rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. The company incurred issuance costs of $5 million in connection with the senior notes which have been included in “Other assets” in the condensed consolidated balance sheet. These debt issuance costs are being amortized to interest expense over the term of the senior notes.

 

Upon the closing of the offering of the senior notes, we entered into interest rate swaps with an aggregate notional amount of $600 million. Under the interest rate swaps, we will receive fixed-rate interest payments and will make payments based on the six month US dollar London inter-bank offered rate (“LIBOR”). The economic effect of these swaps will be to convert the fixed-rate interest expense on the senior notes to a variable LIBOR-based interest rate. The swaps are accounted for as a fair value hedge of the

 

14



 

interest rate risk inherent in the senior notes and therefore the fair value of the swap will be recorded on our balance sheet at each period end until maturity in 2017. In addition, as a result of the fair value hedge, the senior notes are reflected on our balance sheet at fair value, reflecting the change in their value attributable to interest rate risk. The hedging relationship qualifies for the shortcut method of assessing hedge effectiveness, and consequently we do not expect any ineffectiveness during the life of the swap and any movement in the value of the swap would be reflected in the movement in fair value of the senior notes. At April 30, 2008, the fair value of the swap was an asset of $24 million. As a result, the carrying value of the senior notes now reflects the issued value plus the $24 million to reflect the increase in fair value attributable to interest rate risk.

 

15. COMPREHENSIVE INCOME

 

The following table presents the components of comprehensive income:

 

 

 

Three Months Ended
April 30,

 

 

 

2008

 

2007

 

 

 

(in millions)

 

Net income

 

$

173

 

$

123

 

Other comprehensive income:

 

 

 

 

 

Change in unrealized gain on investments

 

1

 

1

 

Change in unrealized gain (loss) on derivative instruments

 

14

 

(6

)

Translation gain reclassified into earnings related to liquidation of a subsidiary

 

(25

)

 

Foreign currency translation

 

56

 

58

 

Change in deferred net pension cost

 

(2

)

 

Deferred taxes

 

(6

)

 

Comprehensive income

 

$

211

 

$

176

 

 

 

 

Six Months Ended
April 30,

 

 

 

2008

 

2007

 

 

 

(in millions)

 

Net income

 

$

293

 

$

273

 

Other comprehensive income:

 

 

 

 

 

Change in unrealized gain (loss) on investments

 

(21

)

1

 

Change in unrealized gain on derivative instruments

 

8

 

2

 

Translation gain reclassified into earnings related to liquidation of a subsidiary

 

(25

)

 

Foreign currency translation

 

114

 

45

 

Change in deferred net pension cost

 

(3

)

 

Deferred taxes

 

(4

)

(3

)

Comprehensive income

 

$

362

 

$

318

 

 

16. STOCK REPURCHASE PROGRAM

 

On November 15, 2007 our Board of Directors approved a share-repurchase program of up to $2 billion of Agilent’s common stock over the next two years. The following repurchases under the above program were completed in the periods presented below:

 

Three months ended

 

Number of
Common
Stock Repurchased

 

Amount of
Common
Stock Repurchased

 

 

 

(in millions)

 

January 31, 2008

 

6.6

 

$

237

 

April 30, 2008

 

8.3

 

263

 

Program to date as of April 30, 2008

 

14.9

 

$

500

 

 

All such shares and related costs are held as treasury stock and accounted for using the cost method. The remaining amount that is authorized under the plan is $1.5 billion.

 

15



 

17. SEGMENT INFORMATION

 

We are a measurement company, providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. Agilent has two primary businesses — bio-analytical measurement and electronic measurement — each of which comprises a reportable segment. The segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Other factors, including customer base, homogeneity of products, technology and delivery channels, were also considered in determining our reportable segments.

 

A significant portion of the segments’ expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include costs of centralized research and development, legal, accounting, real estate, insurance services, information technology services, treasury and other corporate infrastructure expenses. Charges are allocated to the segments, and the allocations have been determined on a basis that we considered to be a reasonable reflection of the utilization of services provided to or benefits received by the segments.

 

The following tables reflect the results of our reportable segments under our management reporting system. These results are not necessarily in conformity with generally accepted accounting principles in the U.S. The performance of each segment is measured based on several metrics, including adjusted income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.

 

The profitability of each of the segments is measured after excluding share-based compensation, restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, amortization and impairment of other intangibles and other items as noted in the reconciliation below.

 

 

 

Electronic
Measurement

 

Bio-analytical
Measurement

 

Total

 

 

 

(in millions)

 

Three months ended April 30, 2008:

 

 

 

 

 

 

 

Total net revenue

 

$

900

 

$

556

 

$

1,456

 

Segment income from operations

 

$

140

 

$

92

 

$

232

 

Three months ended April 30, 2007:

 

 

 

 

 

 

 

Total net revenue

 

$

857

 

$

463

 

$

1,320

 

Segment income from operations

 

$

121

 

$

76

 

$

197

 

 

 

 

 

 

 

 

 

 

 

Electronic
Measurement

 

Bio-analytical
Measurement

 

Total

 

 

 

(in millions)

 

Six months ended April 30, 2008:

 

 

 

 

 

 

 

Total net revenue

 

$

1,736

 

$

1,113

 

$

2,849

 

Segment income from operations

 

$

235

 

$

194

 

$

429

 

Six months ended April 30, 2007:

 

 

 

 

 

 

 

Total net revenue

 

$

1,653

 

$

947

 

$

2,600

 

Segment income from operations

 

$

211

 

$

169

 

$

380

 

 

The following table reconciles reportable segment results to Agilent’s total enterprise results from operations before taxes:

 

 

 

Three Months Ended
April 30,

 

Six Months Ended
April 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(in millions)

 

Total reportable segments’ income from operations

 

$

232

 

$

197

 

$

429

 

$

380

 

Restructuring and asset impairment

 

(6

)

(10

)

(18

)

(19

)

Share-based compensation

 

(19

)

(40

)

(49

)

(76

)

Donation to Agilent Foundation

 

 

 

 

(20

)

Net translation gain from liquidation of a subsidiary

 

11

 

 

11

 

 

Interest income

 

27

 

44

 

66

 

94

 

Interest expense

 

(29

)

(22

)

(59

)

(45

)

Other income (expense), net

 

(4

)

3

 

 

4

 

Amortization of intangibles and other

 

(16

)

(16

)

(37

)

(39

)

Income from operations before taxes, as reported

 

$

196

 

$

156

 

$

343

 

$

279

 

 

16



 

In the three months ended April 30, 2008 we liquidated a subsidiary and recorded a net translation gain of $11 million which consists of $25 million cumulative translation gain offset by a $14 million loss on a net investment hedge.

 

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets.

 

 

 

Electronic
Measurement

 

Bio-analytical
Measurement

 

Total

 

 

 

(in millions)

 

Assets:

 

 

 

 

 

 

 

As of April 30, 2008

 

$

2,121

 

$

1,476

 

$

3,597

 

As of October 31, 2007

 

$

2,025

 

$

1,307

 

$

3,332

 

 

17



 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (UNAUDITED)

 

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Form 10-Q and our Annual Report on Form 10-K. This report contains forward-looking statements including, without limitation, statements regarding trends, seasonality, cyclicality and growth in the markets we sell into, our strategic direction, our future effective tax rate and tax valuation allowance, earnings from our foreign subsidiaries, remediation activities, new product and service introductions, changes to our manufacturing processes, the use of contract manufacturers, the impact of local government regulations on our ability to pay vendors or conduct operations, our liquidity position, our ability to generate cash from continuing operations, growth in our businesses, our investments, the potential impact of adopting new accounting pronouncements, our financial results, our purchase commitments, our contributions to our pension plans, the selection of discount rates and recognition of any gains or losses for our benefit plans, our cost-control activities, savings and headcount reduction recognized from our restructuring programs and the divestiture of our semiconductor products and semiconductor test businesses, our stock repurchase program, our transition to lower-cost regions, the existence or length of an economic recovery that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed below in “Risks, Uncertainties and Other Factors That May Affect Future Results” and elsewhere in this Form 10-Q.

 

Basis of Presentation

 

The financial information presented in this Form 10-Q is not audited and is not necessarily indicative of our future consolidated financial position, results of operations or cash flows. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, all dates refer to our fiscal year and fiscal periods.

 

Executive Summary

 

Agilent Technologies, Inc. (“we”, “Agilent” or the “company”) is the world’s premier measurement company, providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. Agilent has two primary businesses focused on the electronic measurement market and the bio-analytical measurement market.

 

For the three and six months ended April 30, 2008, total orders were $1.52 billion and $2.93 billion, respectively, an increase of  9 percent and 10 percent in comparison to the same periods last year. For the three and six months ended April 30, 2008 order growth of 2 percentage points was attributable to the Stratagene and Velocity11 acquisitions, which closed  in June 2007 and December 2007, respectively.  The impact of currency accounted for a further 4 percentage points of order growth for Agilent in both of the three and six months ended April 30, 2008, when compared to 2007.

 

Net revenue of $1.46 billion and $2.85 billion for the three and six months ended April 30, 2008 was up 10 percent for both the three and six months when compared to the same periods last year. The Stratagene and Velocity11 acquisitions contributed 2 percentage points of revenue growth in both the three and six months ended April 30, 2008 when compared to 2007. The variation of currency accounted for approximately 4 percentage points of the revenue growth in both the three and six months ended April 30, 2008 when compared to the prior year.

 

Net income for the three and six months ended April 30, 2008 was $173 million and $293 million, respectively, and $123 million and $273 million for the corresponding periods last year.  For the three and six months ended April 30, 2008, interest income decreased $17 million and $28 million, respectively. The decrease in interest income is due to the decrease in interest rates as compared to last year. Currency had no net impact in the year-over-year comparison of net income in the three and six months ended April 30, 2008.

 

In the six months ended April 30, 2008, we generated $329 million of cash from operations compared with $395 million generated in the six months of the prior year. The decrease in year-over-year operating cash was mainly driven by higher tax payments related to the transfer of intellectual property between affiliated entities.

 

 Looking forward, our continued focus will be to grow revenue at a faster rate than the electronic measurement and bio-analytical markets, primarily through increasing market share, expanding our served market size with new products and channels and by complementary acquisitions. Our primary strategy is to pursue profitable growth by expanding our leadership in core/adjacent markets and seeking revenue growth opportunities. Despite the weakness in U.S. capital markets and the slowdown of the U.S. economy, we remain cautiously optimistic about our ability to continue to meet our growth objectives and leverage our operating model. We have built flexibility into our operating model to allocate resources to market and regional opportunities and continue to increase the variability of our cost structure and focus on the reduction of infrastructure expenses.

 

18



 

Critical Accounting Policies and Estimates

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our Condensed Consolidated Financial Statements, which have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. The preparation of condensed consolidated financial statements in conformity with GAAP in the U.S. requires management to make estimates, judgments and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, investment impairments, share-based compensation, retirement and post-retirement benefit plan assumptions, valuation of long-lived assets and accounting for income taxes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates.

 

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements.

 

Share-based compensation. The expected stock price volatility assumption was determined using the implied volatility for our stock awards. We estimate the stock price volatility using the implied volatility of Agilent’s publicly traded, similarly priced, stock options. We have determined that implied volatility is more reflective of market conditions and a better indicator of expected volatility than using historical volatility or a combined method of determining volatility. In reaching this conclusion, we have considered many factors including the extent to which our options are traded and our ability to find traded options with similar terms and prices to the options we are valuing. A 10 percent increase in our estimated volatility from 28 percent to 38 percent would generally increase the value of an award and the associated compensation cost by approximately 25 percent if no other factors were changed.

 

Goodwill and purchased intangible assets. No events occurred or circumstances changed during the six months ended April 30, 2008 that required us to test goodwill or purchased intangibles for impairment.

 

Accounting for income taxes. Effective at the beginning of the first quarter of 2008, we adopted FIN No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109” (“FIN No. 48”). As a result of the implementation, we recognize liabilities for uncertain tax positions based on the two-step approach prescribed in the interpretation. The first step is to evaluate each uncertain tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes.  We reevaluate these uncertain tax positions on a quarterly basis.  This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, and new audit activity.  Such a change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision in the period. See Note 5, “Provision for Taxes”, for additional information, including the effects of adoption on our consolidated financial statements.

 

Other critical accounting policies were unchanged in the three and six months ended April 30, 2008.

 

Adoption of New Pronouncements

 

See Note 3, “New Accounting Pronouncements,” to the condensed consolidated financial statements for a description of new accounting pronouncements.

 

Restructuring and Asset Impairment

 

See Note 13, “Restructuring,” of the condensed consolidated financial statements for more details relating to the restructuring plans and asset impairment activity.

 

Foreign Currency

 

Our revenues, costs and expenses, and monetary assets and liabilities are exposed to changes in foreign currency exchange rates as a result of our global operating and financing activities. We hedge revenues, expenses and balance sheet exposures that are not denominated in the functional currencies of our subsidiaries on a short term and anticipated basis. We do experience some fluctuations

 

19



 

within individual lines of the condensed consolidated statement of operations and balance sheet because our hedging program is not designed to offset the currency movements in each category of revenues, expenses, monetary assets and liabilities. Our hedging program is designed to hedge currency movements on a relatively short-term basis (rolling twelve month period). Therefore, we are exposed to currency fluctuations over the longer term.

 

Results from Operations

 

In the beginning of the third quarter of 2007, we moved the nanotechnology measurement business from the electronics measurement segment to the bio-analytical measurement segment to more closely align with the new materials sciences business in that segment. All segment numbers have been restated historically.

 

Orders and Net Revenue

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

 

 

(in millions)

 

 

 

 

 

Orders

 

$

1,524

 

$

1,400

 

$

2,925

 

$

2,650

 

9

%

10

%

Net revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

Products

 

$

1,214

 

$

1,095

 

$

2,375

 

$

2,160

 

11

%

10

%

Services and other

 

242

 

225

 

474

 

440

 

8

%

8

%

Total net revenue

 

$

1,456

 

$

1,320

 

$

2,849

 

$

2,600

 

10

%

10

%

 

Agilent orders increased 9 percent and 10 percent for the three and six months ended April 30, 2008, respectively, compared to the same periods in 2007. The bio-analytical measurement business maintained consistent order growth of 21 percent for both the three and six month periods ended April 30, 2008. Stratagene and Velocity11 accounted for 7 percentage points of this order growth in both the three and six months ended April 30, 2008 when compared to the prior year. Currency variation accounted for an additional 8 percentage points and 7 percentage points in the order growth of the bio-analytical business in the three and six months ended April 30, 2008, respectively, when compared to 2007. Electronic measurement orders grew modestly by 2 percent and 5 percent, respectively, for the three and six months ended April 30, 2008 with market and regional variation in demand. Currency variation accounted for 2 percentage points and 3 percentage points of order growth for the three and six months ended April 30, 2008, respectively, when compared to the prior year.

 

Agilent net revenue increased 10 percent for both the three and six months ended April 30, 2008, compared to the same periods last year. The bio-analytical measurement business achieved revenue growth of 20 percent and 18 percent, respectively, for the three and six months ended April 30, 2008 with strength in both our chemical analysis and life sciences businesses and in all geographies. Stratagene and Velocity11 accounted for 7 percentage points of this growth for both the three and six months ended April 30, 2008 when compared to the prior year. Currency variation added an additional 6 percentage points of revenue growth for both the three and six months ended April 30, 2008, respectively, when compared to the prior year. Electronic measurement business revenues increased by 5 percent for both the three and six months ended April 30, 2008, respectively, compared with the same periods in the prior year. Currency variation contributed 4 percentage points and 3 percentage points of revenue growth for the three and six months ended April 30, 2008, respectively, when compared to the prior year. Our communications test business grew reasonably well in the three months ended April 30, 2008 with relatively broad-based strength across end markets. General purpose test revenues increased more modestly in the three months ended April 30, 2008.

 

Services and other revenue include revenue generated from servicing our installed base of products, warranty extensions and consulting. Services and other revenue for the three and six months ended April 30, 2008 increased 8 percent as compared to the same periods last year. Service revenue trends tend to lag product revenue due to the deferral of service revenue, most of which is recognized over extended time periods.

 

20



 

Operating Results

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

Total gross margin

 

55.4

%

55.3

%

54.9

%

54.7

%

 

 

Operating margin

 

13.1

%

9.9

%

11.4

%

8.7

%

3

ppts

3

ppts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

183

 

$

173

 

$

364

 

$

341

 

6

%

7

%

Selling, general and administrative

 

$

433

 

$

426

 

$

874

 

$

854

 

2

%

2

%

 

Total gross margins for the three and six months ended April 30, 2008 were flat when compared to the same periods last year. Excluding the impact of currency, gross margins increased by approximately one percentage point for both the three and six months ended April 30, 2008 when compared to the same periods in 2007. Operating margins increased by 3 percentage points for both the three and six months ended April 30, 2008, respectively, compared with the same periods last year.

 

Research and development expenses increased 6 percent and 7 percent for the three and six months ended April 30, 2008, compared to the same periods last year. Approximately 5 percentage points of the increase for the three and six months ended April 30, 2008 has been created by changes in currency movements. We remain committed to bringing new products to the market, and have focused our development efforts on key strategic opportunities in order to align our business with available markets and position ourselves to capture market share.

 

Selling, general and administrative expenses increased by 2 percent for both the three and six months ended April 30, 2008, compared to the same period last year. Excluding the impact of currency, selling, general and administrative expenses decreased 3 percent and 2 percent, respectively, for the three and six months ended April 30, 2008 when compared to the same period last year.

 

At April 30, 2008, our headcount was approximately 19,500 as compared to approximately 18,900 at April 30, 2007. The increase in workforce is entirely due to acquisitions.

 

General Infrastructure and Shared Services

 

Our global infrastructure organization (“GIO”) remains a key component of our operating model and has proactively taken action to fully prepare for potential economic disruptions. GIO, which includes finance, IT and workplace services has aggressively focused on ways to reduce expenses and leverage our infrastructure while continuing to develop the infrastructure to support our Asian business presence and integrate our recent acquisitions.

 

Provision for Income Taxes

 

For the three and six months ended April 30, 2008, we recorded an income tax provision of $23 million and $50 million, respectively, compared to an income tax provision of $33 million and $6 million for the same periods last year. The income tax provision for the three and six months ended April 30, 2008 both include a benefit of $12 million for effectively settled issues related to foreign audits. The tax provision for the three and six months ended April 30, 2008 include a benefit of $2 million and expense of $3 million, respectively, for interest and penalties. The income tax provision for the six months ended April 30, 2007 includes a benefit of $50 million related to the reversal of a tax reserve for potential non-U.S. exposures where the statute of limitations expired. The provisions are recorded for taxes on income generated in jurisdictions other than the U.S., U.K. and the Netherlands where we have partial or full valuation allowances. We intend to maintain partial or full valuation allowances in the U.S., U.K. and the Netherlands until sufficient positive evidence exists to support the reversal of the valuation allowances.

 

For 2008, our current expectation of the annual effective tax rate is 16 percent. The income tax rate is 15 percent for the six months ended April 30, 2008. As noted in the previous paragraph, the tax rate for the three and six months ended April 30, 2008 includes discrete tax events. Excluding the impact of quarterly discrete tax adjustments, we anticipate the full-year 2008 effective tax rate to also be approximately 16 percent. The overall tax rate reflects taxes in all jurisdictions except the U.S. and foreign jurisdictions in which income tax expense or benefit continues to be offset by adjustments to the valuation allowances. This tax rate may change over time as the amount or mix of income and taxes changes. Our effective tax rate is calculated using our projected annual pre-tax income or loss from continuing operations and is affected by research tax credits, the expected level of other tax benefits, the effects of

 

21



 

business acquisitions and dispositions, the impact of changes to valuation allowances, changes in other comprehensive income, as well as changes in the mix of income and losses in the jurisdictions in which we operate that have varying statutory rates.

 

Effective at the beginning of the first quarter of 2008, we adopted FIN No. 48. FIN No. 48 contains a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with SFAS No. 109, “Accounting for Income Taxes.” The first step is to evaluate each uncertain tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon ultimate settlement.

 

As a result of the implementation of FIN No. 48, we increased the liability for net unrecognized tax benefits by $74 million, and accounted for the increase as a cumulative effect of a change in accounting principle that resulted in a decrease to retained earnings of $74 million. The total amount of gross unrecognized tax benefits as of the date of adoption was $909 million. We historically classified unrecognized tax benefits in current taxes payable, or as reductions to tax receivables or net deferred tax assets. As a result of adopting FIN No. 48, approximately $355 million of unrecognized tax benefits and related interest and penalties were reclassified to long-term income taxes payable from current taxes payable. Most of these gross unrecognized tax benefits would affect the effective tax rate, if realized.

 

We continue to include interest and penalties related to unrecognized tax benefits within the provision for income taxes on the condensed consolidated statements of operations. As of the date of adoption of FIN No. 48, we had accrued $35 million for the payment of interest and penalties relating to unrecognized tax benefits.

 

In the U.S. and other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2000. Although the timing and outcome of audit settlements are highly uncertain, we do not believe it is reasonably possible that the unrecognized tax benefits would materially change in the next 12 months.

 

Our U.S. federal income tax returns for 2000 through 2002 have been under audit by the Internal Revenue Service (“IRS”). In August 2007, we received a Revenue Agent’s Report (“RAR”). In the RAR, the IRS proposes to assess a net tax deficiency, after applying available net operating losses from the years under audit and undisputed tax credits, for those years of approximately $405 million, plus penalties of approximately $160 million and interest. If the IRS were to fully prevail, our net operating loss and tax credits generated in recent years would be utilized earlier than they otherwise would have been, and our annual effective tax rate will have increased as a result. The RAR addresses several issues. One issue, however, relating to the use of Agilent’s brand name by our foreign affiliates, accounts for a majority of the claimed tax deficiency. We believe that the claimed IRS adjustment for this issue in particular is inconsistent with applicable tax laws and that we have meritorious defenses to this claim. Therefore, we have not included any tax for this item in our tax provision for 2007 or for either of the first two quarters of 2008. We have filed a formal protest and expect to meet with the Appeals Office of the IRS. In the protest, we have vigorously opposed the claim associated with Agilent’s brand name, and most of the other claimed adjustments proposed in the RAR. In April of 2008, we received a rebuttal to our formal protest, and after reviewing the IRS’s arguments, our assessment of the risks remains the same. The final resolution of the proposed adjustments is uncertain and may take several years. Based on current information, it is our opinion that the ultimate disposition of these matters is unlikely to have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

For all U.S. and other tax jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes and interest will be due. If our estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary.

 

Segment Overview

 

Agilent is the world’s premier measurement company providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. Agilent has two primary businesses focused on the electronic measurement market and the bio-analytical measurement market.

 

Electronic Measurement

 

Our electronic measurement business provides standard and customized solutions that are used in the design, development, manufacture, installation, deployment and operation of electronic equipment and systems and communications networks and services.

 

22



 

Orders and Net Revenue

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

 

 

(in millions)

 

 

 

 

 

Orders

 

$

928

 

$

909

 

$

1,771

 

$

1,693

 

2

%

5

%

Net revenue

 

$

900

 

$

857

 

$

1,736

 

$

1,653

 

5

%

5

%

 

Orders for the three and six months ended April 30, 2008, grew 2 percent and 5 percent, respectively, when compared to the same periods last year. Foreign currency movements accounted for the year-over-year growth for the past three months and for 3 percentage points of growth for the past six months. In our communications test business, we saw strength in our wireless manufacturing and broadband R&D and manufacturing markets with steady growth in wireless R&D. In our general purpose test business, sustained strength in the aerospace and defense market offset ongoing weakness in the semiconductor test market.

 

Revenue for the three and six months ended April 30, 2008, grew 5 percent for both periods when compared to the same periods last year, reflecting strength in the communications test market and modest growth in general purpose test. The comparative weakness of the U.S. dollar accounted for approximately 4 percentage points and 3 percentage points of the revenue growth in the three and six months ended April 30, 2008, respectively. Regionally, for the three months ended April 30, 2008, revenue from the Americas and Europe grew 1 percent each, while Asia revenue grew 11 percent with significant year-over-year improvement in Japan.

 

General purpose test revenue of $537 million and $1,033 million for the three and six months ended April 30, 2008, grew 2 percent and 3 percent, respectively, compared to the same periods last year. Within general purpose test, strength in aerospace and defense was partially offset by weakness in the computer and semiconductor test market. Other general purpose test markets experienced good demand. Intelligence, surveillance, and reconnaissance markets remained strong applications for radio frequency (“RF”) content, with other RF applications being used in shipboard and space-based radar, as well as communications and networking. The computer and semiconductor test markets were down compared to last year due to a sharp decline in the parametric test market, while digital test improved. Other general test markets were mixed with steady growth in basic instruments and continued pressure in electronic manufacturing test markets.

 

Communications test revenues of $363 million and $703 million for the three and six months ended April 30, 2008, increased 11 percent and 8 percent, respectively, compared to the same periods last year. Growth for the three months ended April 30, 2008, was driven by the wireless manufacturing test market, as well as broadband R&D and manufacturing test, while wireless R&D revenue grew steadily. Weakness in the communications test market was isolated to the network installation and maintenance market. Investment in the wireless R&D test market continues to focus on high-speed applications, as well as pre-conformance and interoperability test solutions. In addition, WiMax test solutions and next generation cellular technologies test, such as long-term evolution, are contributing to steady demand in the communications test market. Strength in the broadband R&D and manufacturing test market is being driven by the convergence of an all internet protocol-based network for service delivery including video, voice, data, and mobile services.

 

Looking forward, we project steady growth in our electronic measurement business. This growth is expected to be driven by our customers’ expansion of wireless 3G coverage and services (high data rate, multi-media services supported by multi-functional handsets), emerging cellular technologies, and continued opportunities in broadband access, voice-over-internet-protocol and fiber-to-the-home, all fueled by consumer demand for voice/data/video converged services. We believe the aerospace and defense market’s overall long-term trend of spending growth in areas of signal intelligence, communications, surveillance and information warfare bode well for long-term growth in test and measurement sales into this market. This growth potential could be mitigated by potential slowdowns in spending on new communications technologies, governmental budgetary shifts, continued contraction in the semiconductor test market and the current overall macro-economic uncertainty in the U.S.

 

Operating Results

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

Gross margin

 

58.2

%

58.7

%

57.7

%

57.8

%

(1

)ppt

 

Operating margin

 

15.6

%

14.1

%

13.5

%

12.8

%

1

ppt

1

ppt

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

126

 

$

124

 

$

252

 

$

244

 

2

%

3

%

Selling, general and administrative

 

$

257

 

$

258

 

$

515

 

$

500

 

 

3

%

 

23



 

Gross margins were flat for the three and six months ended April 30, 2008, compared to the same periods last year, as improvements in volume, product mix and overhead cost were largely offset by the impact of foreign currency movements.

 

Research and development expenses for the three and six months ended April 30, 2008 increased 2 percent and 3 percent compared to the same periods last year. This increase was driven largely by the impact of foreign currency as operational and discretionary spending net of currency declined year-over-year.

 

Selling, general and administrative expenses for the three and six months ended April 30, 2008, were flat and increased 3 percent, respectively, compared to the same periods last year. Expenses in these periods increased due to the impact of foreign currency movements, while operational and discretionary spending net of currency declined significantly year-over-year, reflecting the structural savings delivered through cost reduction programs.

 

Income from operations for the three and six months ended April 30, 2008 increased $19 million and $24 million, respectively, while our operating margins for both periods improved 1 percentage point. Higher revenues, improvements in product mix and lower spending were offset by the unfavorable impact of currency movements.

 

Bio-analytical Measurement

 

Our bio-analytical measurement business provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Our key product categories include: microarrays, microfluidics, gas chromatography, liquid chromatography, mass spectrometry, laser interferometry and microscopy, software and informatics, and related consumables, reagents and services.

 

Orders and Net Revenue

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

 

 

(in millions)

 

 

 

 

 

Orders

 

$

596

 

$

491

 

$

1,154

 

$

957

 

21

%

21

%

Net revenue

 

$

556

 

$

463

 

$

1,113

 

$

947

 

20

%

18

%

 

Our bio-analytical measurement business continues to see sustained momentum with double-digit growth in orders and revenues on a quarter- and year-to-date basis. Results were consistent with our normal seasonal patterns and reflected the strong demand across virtually all of our markets.

 

Orders for the three and six months ended April 30, 2008 grew 21 percent in both periods, when compared to the same periods last year (the Stratagene and Velocity11 acquisitions contributed 7 percent of this growth). Currency accounted for 8 percent and 7 percent of the growth in orders for the three and six months ended April 30, 2008 when compared to the same periods last year. In our chemical analysis business, we continue to see strength from petrochemical and food safety market, and sustained growth in environmental markets. In life sciences, we saw sustained demand from pharmaceutical and biotechnology companies, contract research organizations, academic and government markets.

 

Revenues for the three and six months ended April 30, 2008 grew 20 percent and 18 percent, respectively, compared to the same periods last year with solid results seen across both life sciences and chemical analysis end markets. These results include the impact of the Stratagene and Velocity11 acquisitions. The core strengths of Stratagene and Velocity11 will allow us to better serve life sciences customers through synergies enabling us to enhance our mutual product offerings and improve specific application solutions. Stratagene and Velocity11 contributed 7 percent of this growth for both the three and six months ended April 30, 2008. Currency accounted for approximately 6 percent of the growth in revenues for both the three and six months ended April 30, 2008, when compared to the same periods last year. We had solid quarterly growth across all geographies with the Americas up 19 percent, Europe up 13 percent and Asia up 32 percent year-over-year. In life sciences, we saw solid performance across the pharmaceutical and biotechnology markets as well as the academic and government markets. In chemical analysis, our sales in the petrochemical, environmental and food safety markets performed well. Proprietary supplies saw double-digit quarterly growth with strength across both liquid chromatography (“LC”) and gas chromatography (“GC”) columns with applications in both the life sciences and chemical analysis businesses.

 

Chemical analysis revenue grew 11 percent and 10 percent for the three and six months ended April 30, 2008 reflecting solid growth in all major end markets. Chemical analysis continues to see strength from petrochemical and food safety market, and

 

24



 

sustained growth in environmental testing solutions. High petrochemical profits continued to drive capital investments in both instrument replacements and upgrades. Environmental, one of our larger markets, saw modest revenue growth for the three and six months ended April 30, 2008. Investments in this space have been cyclical especially in the U.S. with the tightening of federal and state budgets. This, however, was offset by the increased testing needs on drinking water, solid waste testing and air monitoring—especially in China and India. Forensics, our smallest market in chemical analysis, saw modest growth. Petrochemical also grew consistently with year-over-year revenue growth in the first and second quarters as customers transitioned to our new GC and gas chromatography/mass spectrometry (‘‘GC/MS”) products. We are also benefitting from system replacements in Americas and Europe, construction of new refineries in India and China, and worldwide demand for alternative fuels such as bio-diesel. Food testing also posted strong revenue growth in the three and six months ended April 30, 2008. Growth in this sector was driven by recent food safety issues in the U.S causing updated regulations in China, Malaysia and India and by overall increases made to regulatory standards worldwide. Material sciences, one of our smaller markets, is experiencing a decrease in sales into the semiconductor-related capital equipment market driven by weakness in the dynamic random access memory (“DRAM”) market.

 

Life sciences revenue grew 33 percent and 28 percent for the three and six months ended April 30, 2008, reflecting solid growth in all major end markets. The Stratagene and Velocity11 acquisitions accounted for 17 percent and 16 percent of the growth for the three and six months ended April 30, 2008, when compared to the same periods last year. In life sciences, we saw good demand from pharmaceutical and biotechnology companies, contract research organizations, academic and government markets. For the three and six months ended April 30, 2008 both our pharmaceutical and biotech market and our academic and government market grew at a strong rate. Our academic and government revenues nearly doubled including the Stratagene acquisition. Our acquisition of Stratagene is bolstering our coverage in academia and government customer accounts. Academic research is moving toward the use of high-end mass spectrometry instrumentation to answer complex biological questions and enhance research on proteins, peptides, and small molecules. The market continues to see more partnerships and collaborations between not-for-profit organizations and big pharma and biotech. In Asia Pacific, governments are investing in the modernization of their healthcare systems and in improving the quality of pharmaceuticals they produce. In the U.S., National Institutes of Health (“NIH”) funding appears to be flat to declining—making it difficult for suppliers of instruments and life sciences tools to grow significantly in this space. From a product perspective, revenue growth for this market was driven by demand for our new 7890 GC platform, GC/MS system , inductively coupled plasma mass spectrometry (“ICP-MS”) based solutions, bioanalyzers and qualitative polymerase chain reaction (“QPCR”) platforms (reagents and instrumentation). We also see sustained performance from our 1200-series LC platform, particularly the rapid resolution system, high-performance LC columns, single quad-, triple quad, quadrupole time of flight mass spectrometers, and microarrays.

 

Looking forward, we expect our chemical analysis market growth to be driven by investments in food safety on a global basis and in environmental testing in China, India and selected Eastern European countries. Our LC/MS and GC/MS systems are well positioned to address these market needs. In life sciences we are uniquely positioned with our recent acquisitions to expand the range of our technology offering along the life sciences workflow. Workflow solutions can span from sample delivery and preparation through sample measurement to data analysis and management. In addition, our ongoing expansion of the liquid chromatography / mass spectroscopy (“LC/MS”) portfolio, augmented with focused R&D programs will enable Agilent to address the high-growth proteomics and metabolomics market needs.

 

Operating Results

 

 

 

Three Months Ended

 

Six Months Ended

 

Year over Year Change

 

 

 

April 30,

 

April 30,

 

Three

 

Six

 

 

 

2008

 

2007

 

2008

 

2007

 

Months

 

Months

 

Gross margin

 

53.6

%

53.4

%

53.8

%

53.5

%

 

 

Operating margin

 

16.6

%

16.4

%

17.4

%

17.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

50

 

$